http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112370431-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 |
| filingDate | 2020-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112370431-B |
| titleOfInvention | Tizanidine hydrochloride pharmaceutical composition and preparation method thereof |
| abstract | The invention relates to a preparation method of a tizanidine hydrochloride pharmaceutical composition, which is characterized in that part of lactose in a prescription is micronized and then mixed with raw materials and other auxiliary materials, and the mixture is prepared into tablets by a powder direct-compression process, so that the tizanidine hydrochloride pharmaceutical composition can be quickly dissolved out in the initial stage of release, the release in the middle and later stages is smooth, the full release of the drug is not influenced in the final stage, adverse reactions related to dosage can be reduced, the final release of the drug can be ensured, and the overall curative effect can be ensured. The prescription process is simple and easy to implement and is easy for commercial production. |
| priorityDate | 2020-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.